Insider · CIK 0001746298

Struthers Richard Scott

Reports to the SEC for 2 companies · PALO ALTO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001746298

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−111K sh	$85.00	−$9.44M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−244K sh	$64.98	−$15.9M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−137K sh	$85.00	−$11.6M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−106K sh	$85.00	−$9.01M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−172K sh	$59.81	−$10.3M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−100K sh	$85.00	−$8.5M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−248K sh	$85.00	−$21.1M	176,663
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−80K sh	$85.00	−$6.8M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−111K sh	$85.00	−$9.44M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−111K sh	$85.00	−$9.44M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−111K sh	$85.00	−$9.44M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−288K sh	$65.36	−$18.8M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−240K sh	$41.49	−$9.96M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−313K sh	$48.14	−$15.1M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−259K sh	$69.71	−$18.1M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−1,000 sh	$85.00	−$85K	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−110K sh	$85.00	−$9.35M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−177K sh	$85.00	−$15M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−196K sh	$62.39	−$12.2M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−228K sh	$41.21	−$9.4M	0
2026-08-07	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−4,422 sh	—	—	195,578
2026-08-07	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−4,995 sh	—	—	244,205
2026-08-07	CRNXCrinetics Pharmaceuticals, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+6,542 sh	$15.29	+$100K	419,711
2026-08-07	CRNXCrinetics Pharmaceuticals, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+4,995 sh	$20.02	+$100K	424,706
2026-08-07	CRNXCrinetics Pharmaceuticals, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+4,422 sh	$22.61	+$100K	413,169
2026-08-07	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−6,542 sh	—	—	259,058
2026-08-07	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−3,969 sh	—	—	172,281
2026-08-07	CRNXCrinetics Pharmaceuticals, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+3,969 sh	$25.19	+$100K	408,747
2026-05-29	CRNXCrinetics Pharmaceuticals, Inc.G Gift	Director, President & CEO	GGift	−111K sh	—	—	1,000
2026-05-29	CRNXCrinetics Pharmaceuticals, Inc.G Gift	Director, President & CEO	GGift	+111K sh	—	—	111,100
2026-05-29	CRNXCrinetics Pharmaceuticals, Inc.G Gift	Director, President & CEO	GGift	+111K sh	—	—	111,100
2026-05-29	CRNXCrinetics Pharmaceuticals, Inc.G Gift	Director, President & CEO	GGift	−80K sh	—	—	136,805
2026-05-29	CRNXCrinetics Pharmaceuticals, Inc.G Gift	Director, President & CEO	GGift	+222K sh	—	—	626,978
2026-05-29	CRNXCrinetics Pharmaceuticals, Inc.G Gift	Director, President & CEO	GGift	+222K sh	—	—	223,200
2026-05-29	CRNXCrinetics Pharmaceuticals, Inc.G Gift	Director, President & CEO	GGift	−222K sh	—	—	439,005
2026-05-29	CRNXCrinetics Pharmaceuticals, Inc.G Gift	Director, President & CEO	GGift	−222K sh	—	—	216,805
2026-05-29	CRNXCrinetics Pharmaceuticals, Inc.G Gift	Director, President & CEO	GGift	+80K sh	—	—	80,000
2026-05-29	CRNXCrinetics Pharmaceuticals, Inc.G Gift	Director, President & CEO	GGift	−111K sh	—	—	515,878
2026-05-29	CRNXCrinetics Pharmaceuticals, Inc.G Gift	Director, President & CEO	GGift	−111K sh	—	—	404,778
2026-05-29	CRNXCrinetics Pharmaceuticals, Inc.G Gift	Director, President & CEO	GGift	+111K sh	—	—	111,100
2026-05-29	CRNXCrinetics Pharmaceuticals, Inc.G Gift	Director, President & CEO	GGift	+111K sh	—	—	111,100
2026-05-29	CRNXCrinetics Pharmaceuticals, Inc.G Gift	Director, President & CEO	GGift	−111K sh	—	—	112,100
2026-03-16	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Director, President & CEO	SSale	−13.2K sh	$37.11	−$490K	413,563
2026-03-16	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Director, President & CEO	SSale	−8,785 sh	$37.77	−$332K	404,778
2026-02-23	CRNXCrinetics Pharmaceuticals, Inc.A Award	Director, President & CEO	AAward	+62K sh	—	—	426,759
2026-02-23	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+228K sh	—	—	228,000
2025-12-18	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−28.4K sh	—	—	259,058
2025-12-18	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−16.3K sh	—	—	0
2025-12-18	CRNXCrinetics Pharmaceuticals, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+28.4K sh	$15.29	+$434K	364,759
2025-12-18	CRNXCrinetics Pharmaceuticals, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+16.3K sh	$9.28	+$152K	336,359

Recent filings

Accepted (ET)
Sep 14
Struthers Richard Scott0001628280-26-059882
SEC(opens sec.gov)

Companies

Address

1001 PAGE MILL ROAD BUILDING 4, SUITE 200B

PALO ALTO, CA, 93404